You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》野村升微創醫療(00853.HK)目標價至8.81元 料公司可達成全年收入指引
阿思達克 07-15 11:00
野村發表研究報告指,預計微創醫療(00853.HK)上半年收入按年增2.1%至5.7億美元。主要業務方面,在去年同期高基數下,預期心血管、整形外科及CRM業務於期內分別增長2%、3%及2%,即分別為9,000萬、1.37億和1.19億美元。考慮到較低的毛利率和審慎的開支控制,預計公司上半年的經營虧損為2,300萬美元。由於非核心業務的出售可能帶來收益,估計公司將錄得淨虧損1,800萬美元。 至於下半年,該行預期下半年基數較低,微創醫療將有較高的收入增長,料增長率為24%,又料淨虧損為6,700萬美元。該行相信,公司可望達到2025財年收入增長介乎10%至11%的指引,但需要控制好經營開支,以符合其可轉換債券的條款。 該行將公司目標價由7.73港元上調至8.81港元,評級為「中性」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account